ClinicalTrials.gg
Not yet recruitingNCT07552974CBD-BJJ-RCTUpdated Jul 27, 2026

CBD Supplementation in Brazilian Jiu-Jitsu Athletes

A Phase 2/3 interventional study of CBD Isolate 100mg BID and Placebo in Pro and Anti Inflamatory Cytokines, Pain and Sleep, sponsored by Associação Pan-Americana Multidisciplinar de Endocanabinologia. Not yet recruiting at 1 site in Brazil. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Associação Pan-Americana Multidisciplinar de Endocanabinologia · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 211 studies in Pain with a site in Brazil — 19 open to participants now, 21 under way, 1 of them phase 3. Pain · Brazil.

Planned enrollment
46th of 204
100 · median 60
Started
2027
the only one that year
Phase 2/3
4 of 211
1 open now
Primary completion
2027-02
later than 18 of 20 live
Registered
208th of 211
by date

Among the 211 studies in Pain with a site in Brazil, this one is the 46th largest by planned enrollment of the 204 interventional ones that give a count, is the only one that started in 2027, is one of 4 in phase 2/3, reaches primary completion later than 18 of the 20 other live ones, and was the 208th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

19 of the 211 studies in Pain with a site in Brazil are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 40 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 211 studies in Pain with a site in Brazil, or all of them as a file.
02

Study summary

Brazilian Jiu-Jitsu (BJJ) is a high-intensity martial art that imposes significant physical and physiological demands on practitioners, including rigorous training and frequent competitions, which can result in chronic inflammation, delayed-onset muscle soreness (DOMS), sleep disturbances, and reduced quality of life. Effective recovery strategies are essential to optimize athletic performance and longevity in the sport.

Cannabidiol (CBD), a non-psychotomimetic phytocannabinoid derived from Cannabis sativa, has emerged as a promising therapeutic agent due to its anti-inflammatory, analgesic, anxiolytic, and neuroprotective properties.

Preclinical studies indicate that CBD modulates inflammatory pathways, such as inhibition of NF-κB and NLRP3, thereby reducing pro-inflammatory cytokines such as IL-6, TNF-α, IL-8, and IL-1β, while increasing the anti-inflammatory cytokine IL-10.

In clinical contexts, CBD has shown potential to attenuate DOMS and improve sleep without the adverse effects associated with non-steroidal anti-inflammatory drugs (NSAIDs). However, evidence in BJJ athletes remains limited, with gaps in the translation of preclinical findings to healthy athletic populations.

The prevalence of injuries in combat sports can reach 28%, with contusions and sprains being common and further exacerbating inflammation and pain. Although approximately 23.4% of athletes report cannabis use, there is a lack of randomized controlled trials (RCTs) specifically for BJJ evaluating isolated CBD at standardized doses.

Furthermore, concerns regarding hepatotoxicity, monitored through enzymes such as AST and ALT, require rigorous safety evaluation.

This protocol describes an RCT to investigate the effects of 200 mg/day of isolated CBD for 12 weeks in BJJ athletes, focusing on sensitive inflammatory markers (IL-6 as the primary pro-inflammatory marker and IL-10 as the anti-inflammatory marker), pain, sleep, and quality of life.

The study aims to address gaps identified in systematic reviews and provide an evidence-based foundation for future recommendations.

Read the detailed description

Abstract Objective: To evaluate the effects of chronic supplementation with isolated cannabidiol (CBD) on inflammatory markers, pain perception, sleep quality, and quality of life in Brazilian Jiu-Jitsu (BJJ) athletes in a randomized, double-blind, placebo-controlled clinical trial.

Methods: One hundred and twenty-eight BJJ athletes (aged 18-40 years, with a minimum of 2 years of practice and training ≥3 times per week) will be recruited. Participants will be randomized in a 1:1 ratio to receive 100 mg of isolated CBD or placebo twice daily (total 200 mg/day) for 12 weeks.

Primary Outcomes: Serum levels of pro-inflammatory cytokines (IL-6, TNF-α, IL-8, IL-1β) and the anti-inflammatory cytokine (IL-10), measured by ELISA or multiplex assays.

Secondary Outcomes: Pain (Visual Analog Scale - VAS), sleep quality (Pittsburgh Sleep Quality Index - PSQI), quality of life (SF-36 and Athlete Life Quality Scale - ALQS), and safety (hepatic enzyme AST).

Assessments will be conducted at baseline and at weeks 4, 8, and 12. Statistical Analysis: Linear mixed-effects models for repeated measures will be used, with the intention-to-treat (ITT) population as the primary analysis.

Expected Results: Significant reduction in inflammatory markers and improvement in secondary outcomes in the CBD group, with an acceptable safety profile.

Keywords:

Cannabidiol; Brazilian Jiu-Jitsu; Inflammation; Muscle Pain; Sleep; Quality of Life.

Introduction Brazilian Jiu-Jitsu (BJJ) is a high-intensity martial art that imposes significant physical and physiological demands on practitioners. Rigorous training and frequent competitions can lead to chronic inflammation, delayed-onset muscle soreness (DOMS), sleep disturbances, and reduced quality of life. Effective recovery strategies are essential to optimize athletic performance and longevity in the sport.

Cannabidiol (CBD), a non-psychotomimetic phytocannabinoid derived from Cannabis sativa, has emerged as a promising therapeutic agent due to its anti-inflammatory, analgesic, anxiolytic, and neuroprotective properties.

Preclinical studies indicate that CBD modulates inflammatory pathways, such as inhibition of NF-κB and NLRP3, reducing pro-inflammatory cytokines such as IL-6, TNF-α, IL-8, and IL-1β, while increasing the anti-inflammatory cytokine IL-10.

In clinical settings, CBD has demonstrated potential to attenuate DOMS and improve sleep without the adverse effects associated with non-steroidal anti-inflammatory drugs (NSAIDs). However, evidence specifically in BJJ athletes remains limited, with significant gaps in translating preclinical findings to healthy athletic populations.

The prevalence of injuries in combat sports can reach 28%, with contusions and sprains being common and further exacerbating inflammation and pain. Although approximately 23.4% of athletes report cannabis use, there is a lack of randomized controlled trials (RCTs) specifically designed for BJJ evaluating isolated CBD at standardized doses.

Furthermore, concerns regarding hepatotoxicity, monitored through liver enzymes such as AST and ALT, require rigorous safety assessment.

This protocol describes a randomized controlled trial to investigate the effects of 200 mg/day of isolated CBD for 12 weeks in BJJ athletes, focusing on sensitive inflammatory markers (IL-6 as the primary pro-inflammatory marker and IL-10 as the anti-inflammatory marker), pain, sleep, and quality of life.

The study aims to address gaps identified in systematic reviews and provide an evidence-based foundation for future recommendations.

Materials and Methods Study Design This is a randomized, double-blind, placebo-controlled clinical trial with two parallel groups (CBD vs. placebo) lasting 12 weeks. Randomization will be stratified by sex and training level (2-5 years vs. >5 years), generated by computer (R software, blockrand package) in a 1:1 ratio.

Blinding will involve participants, investigators, and assessors, with interventions identical in appearance, packaging, and taste. The study will follow CONSORT guidelines and will be registered on an international platform (ClinicalTrials.gov).

Study Population One hundred and twenty-eight BJJ athletes will be recruited through partner academies in São Paulo, Brazil. The sample size was calculated to detect a 30% reduction in IL-6 (standard deviation 40%, α = 0.05, power 80%, with adjustment for 15% dropout).

03

Conditions studied

  • Pro and Anti Inflamatory Cytokines
  • Pain
  • Sleep
  • Quality of Life

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 40 years;
  • Minimum 2 years of BJJ practice;
  • Training at least 3 times per week;
  • Free from injuries that prevent training or competition;
  • No current or recent cannabis use;
  • Signed Form (ICF).

Exclusion criteria

Exclusion Criteria:

  • History of hepatic, renal, or cardiovascular diseases;
  • Use of medications that may interact with CBD (e.g., anticoagulants);
  • Allergy or known to cannabinoids;
  • Pregnancy or planning to become pregnant;
  • Participation in another clinical study within the last 30 days.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Arm CBD, recieving 100mg BID

    CBD 200mg daily

    Drug: CBD Isolate 100mg BID

  • Placebo comparator
    Placebo, recieving MCT OIL (equivalent volume of 100mg of CBD) BID

    Placebo BID

    Other: Placebo

Interventions

  • DrugCBD Isolate 100mg BID

    Treated for 12 weeks

    Also known as: CBD200

  • OtherPlacebo

    Equivalent volume of MCT BID

    Also known as: PLACEBOBID

06

What researchers measure

Primary outcomes

  1. Inflammatory cytokines

    Serum levels of pro-inflammatory cytokines (IL-6) and anti-inflammatory cytokine (IL-10), measured by ELISA/multiplex. (pg/mL)

    Time frame: From enrollment to the end of treatment at 12 weeks

Secondary outcomes

  1. Pain change from baseline. Visual Analogue Scale (VAS)

    Measure with Visual Analogue Scale. Scoring (0-100mm line): 0 mm to 4 mm indicates no pain, 5 mm to 44 mm is mild pain, 45 mm to 74 mm is moderate pain, and 75 mm to 100 mm is severe pain.

    Time frame: From enrollment to the end of treatment at 12 weeks

  2. Sleep quality improvement from baseline

    Measured with the PSQI. Pittsburgh Sleep Quality Index is a self-report questionnaire that assesses sleep quality over a 1-month interval. The measure consists of 19 individual items, creating 7 components that produce a global score. In English, when describing the PSQI scoring categories, we typically use the following phrasing: Scoring Categories: 0 to 5 points: Good sleep quality. 6 to 10 points: Poor sleep quality. 11 to 15 points: Very poor sleep quality. 16 to 21 points: Extremely poor sleep quality.

    Time frame: From enrollment to the end of treatment at 8 weeks

  3. Improvement in quality of life

    Measured with the Medical Outcomes Study 36-Item Short-Form Health Survey (SF 36). The SF-36 is a generic quality-of-life questionnaire consisting of 36 items that assess 8 physical and mental health domains. Widely used and easy to administer (taking 5 to 10 minutes), it is scored from 0 (worst health) to 100 (best health).

    Time frame: From enrollment to the end of treatment at 12 weeks

  4. Athlete Quality Of Life

    Mesured with the Athlete Life Quality Scale (ALQS). A 15-item, validated tool developed by N.B. Gentner in 2004 to measure the holistic well-being of collegiate athletes. It assesses five key factors: general life satisfaction, physical satisfaction, team/sport satisfaction, primary social satisfaction, and recovery/social satisfaction. higher rates indicate ing a higher level of satisfaction.

    Time frame: From enrollment to the end of treatment at 12 weeks

07

Study locations

1 site
  • APMC
    São Paulo, São Paulo 09060-650, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Feb 2027, 1 month later.

Of 35 non-industry phase 2/3 interventional studies under Pain, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 1 month is below that.

Counting every sponsor, half of 41 studies reached it within 20 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Apr 27, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Feb 1, 2027
CompletionEst.
Jul 31, 2027
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07552974
Lead sponsor
Associação Pan-Americana Multidisciplinar de Endocanabinologia
Responsible party
Sponsor
First posted
Apr 27, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Jul 27, 2026

Study contacts

Jose Wilson N V Andrade, MD
Contact
dr.jwilsonandrade@gmail.com
+55 11 971905328
Jose Wilson N V Andrade, MD
principal investigator · APMC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion